Xufen Yu

23PUBLICATIONS
99CO-AUTHORS
Molecular targetsPredictive and prognostic markersMedical devicesInjury preventionHealth and ecological risk assessment
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Oct 01, 2026
Development of A10P3C, an isoform-selective inhibitor of EGLN2, for targeting breast cancer.

|Aug 14, 2026
An EZH2-SREBP2 axis promotes cholesterol biosynthesis and represents a noncanonical vulnerability in tumorigenesis.

|Jul 08, 2026
RIMTAC: A Novel Degrader Design Platform by Indirect VHL-Recruitment via RIPK1.

|Jun 17, 2026
Unique Cysteine-Directed Covalent Inhibition of PRMT1 Suppresses Breast Tumorigenesis.

|May 13, 2026
Targeted Degradation of Prolyl Hydroxylase Domain Enzyme 1 (PHD1) as a Novel Therapeutic Strategy for Acetaminophen-Induced Acute Liver Injury.

|Apr 17, 2026
ELMO2 is a therapeutic vulnerability in mesenchymal-like and drug-resistant non-small cell lung cancer.

Pageof 4

Frequent Collaborators

18 joint publications

Jian Jin

6 joint publications

Gang Greg Wang

5 joint publications

H Ümit Kaniskan

2 joint publications

Jithesh Kottur